Suppr超能文献

长链非编码RNA SLC9A3-AS1通过海绵吸附微小RNA-760促进非小细胞肺癌的肿瘤发生,并可能作为非小细胞肺癌患者的预后预测指标。

lncRNA SLC9A3-AS1 Promotes Oncogenesis of NSCLC via Sponging microRNA-760 and May Serve as a Prognosis Predictor of NSCLC Patients.

作者信息

Huang Xiuming, Huang Mingfang, Chen Minbiao, Chen Xianshan

机构信息

Department of Thoracic Surgery, Hainan General Hospital, Haikou, Hainan, 570311, People's Republic of China.

出版信息

Cancer Manag Res. 2022 Mar 9;14:1087-1098. doi: 10.2147/CMAR.S352308. eCollection 2022.

Abstract

BACKGROUND

Non-small cell lung cancer (NSCLC) is a prevalent type of lung cancer worldwide. Long noncoding RNA (lncRNA) SLC9A3-AS1 is reported to play a carcinogenic role in nasopharyngeal carcinoma, but its full-scale role in NSCLC remains elusive.

METHODS

SLC9A3-AS1 expression was detected in serum and tissue of NSLCC patients and NSCLC cell lines. The effects of SLC9A3-AS1 on NSCLC proliferation, migration and invasion were evaluated using CCK-8 and transwell assays. In addition, the potential downstream molecules of SLC9A3-AS1 were searched and explored by bioinformatics analysis, RT-qPCR, dual-luciferase reporter, and rescue experiments.

RESULTS

SLC9A3-AS1 was upregulated in NSCLC tissues and cell lines. SLC9A3-AS1 possessed a favorable ability in diagnosing NSCLC. A high level of SLC9A3-AS1 was associated with poor prognosis in NSCLC patients. Functionally, SLC9A3-AS1 knockdown inhibited cell proliferation, migration, and invasion of NSCLC cells. Mechanistically, SLC9A3-AS1 acted as competing endogenous RNA for miR-760 to regulate NSCLC progression. In addition, rescue assay showed that downregulation of miR-760 could reverse the modulatory activity of SLC9A3-AS1 knockdown on NSCLC cells.

CONCLUSION

SLC9A3-AS1 was upregulated in NSCLC, and SLC9A3-AS1 knockdown hindered NSCLC progression through targeting miR-760, suggesting that it may prove to be a novel biomarker and therapeutic target for NSCLC.

摘要

背景

非小细胞肺癌(NSCLC)是全球范围内一种常见的肺癌类型。据报道,长链非编码RNA(lncRNA)SLC9A3-AS1在鼻咽癌中发挥致癌作用,但其在NSCLC中的全面作用仍不清楚。

方法

检测NSLCC患者血清和组织以及NSCLC细胞系中SLC9A3-AS1的表达。使用CCK-8和transwell实验评估SLC9A3-AS1对NSCLC增殖、迁移和侵袭的影响。此外,通过生物信息学分析、RT-qPCR、双荧光素酶报告基因和拯救实验搜索并探索SLC9A3-AS1潜在的下游分子。

结果

SLC9A3-AS1在NSCLC组织和细胞系中上调。SLC9A3-AS1具有良好的NSCLC诊断能力。高水平的SLC9A3-AS1与NSCLC患者的不良预后相关。在功能上,SLC9A3-AS1敲低抑制了NSCLC细胞的增殖、迁移和侵袭。机制上,SLC9A3-AS1作为miR-760的竞争性内源RNA来调节NSCLC进展。此外,拯救实验表明miR-760的下调可逆转SLC9A3-AS1敲低对NSCLC细胞的调节活性。

结论

SLC9A3-AS1在NSCLC中上调,SLC9A3-AS1敲低通过靶向miR-760阻碍NSCLC进展,表明它可能是NSCLC的一种新型生物标志物和治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b51/8921674/d7889dbfb132/CMAR-14-1087-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验